SAM.govRRPV-HPAD
Open
High Performance Antigen Diagnostics
- Response deadline
- Jul 17, 2026 Closed
- Date posted
- Jun 17, 2026
- Source
- Open notice
Description
“High Performance Antigen Diagnostics” Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.
Classifications
Documents (1)
- DownloadRFI RRPV HIPE.pdf.pdf2.0 MB
Contacts
Similar contracts
- Quantitative Analysis of Longitudinal MR ImagesMarylandDue Nov 9, 2026
- ARPA-H Emerging Health Innovators (EHI) InitiativeDistrict of ColumbiaDue Feb 10, 2027
- Q--Amplicon Sequencing ServicesDue Nov 5, 2026
- Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
- Development/Production - Kidney GEC-Specific AAV VectorMODue Nov 4, 2026
- Pre-Clinical Models of Infectious DiseasesDue Dec 7, 2026